James E. Fickenscher, Chief Financial Officer at Zynerba Pharmaceuticals, Inc. (ZYNE), bought 5,200 shares at $19.82 ($103K) on 2017-05-12, disclosed to the SEC on 2017-05-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| ZYNE | SELL | 2022-07-20 | $7K | — | Filing → |
| ZYNE | BUY | 2018-08-07 | $102K | — | Filing → |
| ZYNE | BUY | 2016-12-08 | $99K | — | Filing → |